ATE322285T1 - Verfahren zur induktion der zellulären immunantwort und parenterale impfstoff- zusammensetzungen dazu - Google Patents

Verfahren zur induktion der zellulären immunantwort und parenterale impfstoff- zusammensetzungen dazu

Info

Publication number
ATE322285T1
ATE322285T1 AT99940439T AT99940439T ATE322285T1 AT E322285 T1 ATE322285 T1 AT E322285T1 AT 99940439 T AT99940439 T AT 99940439T AT 99940439 T AT99940439 T AT 99940439T AT E322285 T1 ATE322285 T1 AT E322285T1
Authority
AT
Austria
Prior art keywords
inducing
immune response
polarised
response
cellular immune
Prior art date
Application number
AT99940439T
Other languages
English (en)
Inventor
David James Brayden
Original Assignee
Elan Corp Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Corp Plc filed Critical Elan Corp Plc
Application granted granted Critical
Publication of ATE322285T1 publication Critical patent/ATE322285T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
AT99940439T 1998-09-01 1999-08-31 Verfahren zur induktion der zellulären immunantwort und parenterale impfstoff- zusammensetzungen dazu ATE322285T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9876098P 1998-09-01 1998-09-01

Publications (1)

Publication Number Publication Date
ATE322285T1 true ATE322285T1 (de) 2006-04-15

Family

ID=22270768

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99940439T ATE322285T1 (de) 1998-09-01 1999-08-31 Verfahren zur induktion der zellulären immunantwort und parenterale impfstoff- zusammensetzungen dazu

Country Status (7)

Country Link
EP (1) EP1107783B1 (de)
JP (1) JP4526708B2 (de)
AT (1) ATE322285T1 (de)
AU (1) AU5441299A (de)
CA (2) CA2731995C (de)
DE (1) DE69930753D1 (de)
WO (1) WO2000012125A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08507088A (ja) 1993-12-23 1996-07-30 ゲーエフエフ 免疫応答の増強方法
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US7037528B2 (en) 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
CN1558755A (zh) 2001-09-26 2004-12-29 ���ع��ʹ�˾ 通过分散和除去溶剂或液相制备亚微米大小的纳米颗粒
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
JP4851067B2 (ja) * 2004-01-28 2012-01-11 ホソカワミクロン株式会社 ナノ粒子含有組成物およびその製造方法
ES2246695B1 (es) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Composicion estimuladora de la respuesta inmunitaria que comprende nanoparticulas a base de un copolimero de metil vinil eter y anhidrido maleico.
KR101183705B1 (ko) 2007-02-07 2012-09-17 사이단호진한다이비세이부쯔뵤우겐큐우카이 암의 치료제
AU2008231424A1 (en) * 2007-03-28 2008-10-02 National Institute Of Immunology Polymer particles based vaccine
US10722468B2 (en) 2014-08-14 2020-07-28 Brown University Compositions for stabilizing and delivering proteins
IL283699B (en) * 2014-11-05 2022-09-01 Selecta Biosciences Inc Methods and preparations related to artificial nanocarriers with rapamycin in a super-saturated steady state
GB201918963D0 (en) 2019-12-20 2020-02-05 Provost Fellows Scholars And Other Members Of Board Of Trinity College Dublin Polymeric nanoparticles as vaccine adjuvants

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9209118D0 (en) * 1992-04-28 1992-06-10 Sb 120 Amsterdam Bv Vaccine compositions
DE69630514D1 (de) * 1995-01-05 2003-12-04 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
GB9713156D0 (en) * 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines

Also Published As

Publication number Publication date
AU5441299A (en) 2000-03-21
WO2000012125A1 (en) 2000-03-09
DE69930753D1 (de) 2006-05-18
EP1107783A1 (de) 2001-06-20
JP4526708B2 (ja) 2010-08-18
CA2731995C (en) 2013-05-28
CA2731995A1 (en) 2000-03-09
JP2002523471A (ja) 2002-07-30
EP1107783B1 (de) 2006-04-05
CA2341358A1 (en) 2000-03-09
CA2341358C (en) 2011-04-26

Similar Documents

Publication Publication Date Title
ATE322285T1 (de) Verfahren zur induktion der zellulären immunantwort und parenterale impfstoff- zusammensetzungen dazu
DE69431404D1 (de) Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe
ATE223702T1 (de) Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien
MX9401225A (es) Composicion de vacuna para prevenir la infeccion con influenza en humanos y metodo para su preparacion.
AR003464A1 (es) Método para la producción de una composición apropiada para el uso en composiciones cosméticas que comprende un absorbente de uv orgánico insoluble micronizado.
ATE315405T1 (de) Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
BR9809656A (pt) Composição imunopotencializante
ES2176232T3 (es) Vacuna adecuada para ser utilizada en la prevencion y tratamiento de la infeccion por helicobacter.
DK1187629T3 (da) Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
WO2005049074A3 (en) Methods for modulating the th2 immuneresponse to an antigen by adding or removing activated carbonyl groups from the antigen
UA87665C2 (ru) Авирулентный изолят lawsonia intracellularis европейского происхождения, вакцина для иммунизации животных, применение заявленного авирулентного изолята как вакцины, способ получения вакцины, способ культивирования lawsonia intracellularis, способ диагностики пролиферативной энтеропатии свиней и способ получения антисыворотки к lawsonia intracellularis
TR200403064T2 (tr) Tüberkülozun teşhisi ve immünoterapi yolu ile önlenmesine mahsus yöntemler ve bileşikler.
NO952077D0 (no) Sammensetning bestående av en dendrimer og en aktiv substans okkludert deri
ATE162083T1 (de) Perkutane lymphographie
AUPR011700A0 (en) Composition comprising immunogenic virus sized particles (VSP)
AU9094191A (en) Recombinant avirulent salmonella antifertility vaccines
NO20015074D0 (no) Nye sammensetninger
ES8500997A1 (es) Un metodo para producir un peptido.
IL106968A0 (en) Potentiation of immunogenic response
DE69620271D1 (de) Polyribosylribitol-phosphat enthaltende Haemophilus-influenzae-Typ-b-Impfstoffzubereitung und Verfahren zur deren Herstellung
ATE452651T1 (de) Orale impfstoff-zusammensetzung
ES2182914T3 (es) Inmunopotenciacion inducida de quitosan.
HUP9801223A2 (hu) Eljárás specifikus antigénekre adott antitest válasz fokozására interleukin-10-zel
ATE460943T1 (de) Therapeutische mittel als antikrebs impfstoffadjuvantien und deren therapeutische verfahren
IL139601A0 (en) Compositions and methods of modulating an immune response to an antigen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties